Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.53 |
| ▸ | PPARA | Q07869 | 13/20 | 0.52 |
| ▸ | PPARG | P37231 | 12/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14277936 | 0.90 | PPARA (0.57) | DRD4PPARAPPARG | |
| SCHEMBL18193570 | 0.87 | ATM (0.57) | DRD4PPARAPPARGATMLMNA | |
| SCHEMBL18193569 | 0.87 | ATM (0.57) | DRD4PPARAPPARGATMLMNA | |
| SCHEMBL5460633 | 0.83 | SMN1; SMN2 (0.46) | DRD4PPARAPPARGATMLMNA | |
| SCHEMBL5460640 | 0.83 | SMN1; SMN2 (0.46) | DRD4PPARAPPARGATMLMNA | |
| SCHEMBL18785495 | 0.83 | DRD4 (0.45) | DRD4PPARAPPARGATMLMNA | |
| SCHEMBL5461219 | 0.81 | ATM (0.48) | DRD4PPARAATMLMNASMN1; SMN2 | |
| SCHEMBL5461220 | 0.81 | ATM (0.48) | DRD4PPARAATMLMNASMN1; SMN2 | |
| SCHEMBL13298291 | 0.81 | DRD4 (0.44) | DRD4PPARAPPARGATMLMNA | |
| SCHEMBL13298222 | 0.81 | DRD4 (0.44) | DRD4PPARAPPARGATMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137262-A1 | Low Calcemic, Highly Antiproliferative, Analogs of Calcitriol | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137262-A1 | Low Calcemic, Highly Antiproliferative, Analogs of Calcitriol | VDR, CYP24A1, CYP27B1 | DRD4 2988/4885PPARA 186/4885PPARG 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.